Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia
Author:
Funder
National Key Research and Development Program of China
National Natural Science Foundation of China
NIHR Oxford Biomedical Research Centre
National Institute for Health and Care Research
Peking University People's Hospital
Peking University
Publisher
Elsevier BV
Reference13 articles.
1. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia;Gökbuget;Blood,2018
2. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study;Conter;Blood,2010
3. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia;Brüggemann;Blood,2006
4. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies;Gökbuget;Blood,2012
5. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL);Bassan;Blood,2009
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3